TOKYO, Apr 27 (Pulse News Wire) – Astellas Pharma Inc. (4503.T) reported consolidated results for fiscal year 2026 ending March.
Revenue was ¥2.1 trillion (+11.9% YoY). operating profit was ¥382,633 million (+832.4%). net profit attributable to shareholders was ¥291,575 million (+474.6%).
Total assets stood at ¥2.6 trillion with an equity ratio of 60.4%. The company declared an annual dividend of ¥39 per share. The full-year forecast for the current fiscal year is revenue of ¥2.2 trillion (+3.8%).
Financial results — FY2026/3 (consolidated)
| Metric | Current | YoY |
|---|---|---|
| Revenue | ¥2,139,245M | +11.9% |
| Operating profit | ¥382,633M | +832.4% |
| Net profit | ¥291,575M | +474.6% |
Next period forecast
Revenue
¥2,220,000M
+3.8%Op. profit
¥395,000M
+3.2%Net profit
¥300,000M
+2.9%Source: TDNet filing · Figures in millions of yen
🟢 Confidence: High AI-translated content.